Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study
Year: 2012
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: CONTEXT: People infected with HIV have a higher risk for developing insulin resistance, diabetes, and cardiovascular disease than the general population. Dipeptidyl peptidase IV (DPP4) inhibitors are glucose-lowering medications with pleiotropic actions that may particularly benefit people with HIV, but the immune and virological safety of DPP4 inhibition in HIV is unknown. OBJECTIVE: DPP4 inhibition will not reduce CD4+ T lymphocyte number or increase HIV viremia in HIV-positive adults. DESIGN: This was a randomized, placebo-controlled, double-blind safety trial of sitagliptin in HIV-positive adults. SETTING: The study was conducted at an academic medical center. PARTICIPANTS: Twenty nondiabetic HIV-positive men and women (9.8 ± 5.5 years of known HIV) taking antiretroviral therapy and with stable immune (625 ± 134 CD4+ T cells per microliter) and virological (<48 copies HIV RNA per milliliter) status. INTERVENTION: The intervention included sitagliptin (100 mg/d) vs matching placebo for up to 24 weeks. MAIN OUTCOME MEASURES: CD4+ T cell number and plasma HIV RNA were measured every 4 weeks; fasting serum regulated upon activation normal T-cell expressed and secreted (RANTES), stromal derived factor (SDF)-1α, Soluble TNF receptor II, and oral glucose tolerance were measured at baseline, week 8, and the end of study. ANOVA was used for between-group comparisons; P < .05 was considered significant. RESULTS: Compared with placebo, sitagliptin did not reduce CD4+ T cell count, plasma HIV RNA remained less than 48 copies/mL, RANTES and soluble TNF receptor II concentrations did not increase. SDF1α concentrations declined (P < .0002) in the sitagliptin group. The oral glucose tolerance levels improved in the sitagliptin group at week 8. CONCLUSIONS: Despite lowering SDF1α levels, sitagliptin did not adversely affect immune or virological status, or increase immune activation, but did improve glycemia in healthy, nondiabetic HIV-positive adults. These safety data allow future efficacy studies of sitagliptin in HIV-positive people with cardiometabolic complications.
DOI: 10.1210/jc.2012-3532
Institution: Washington University in St. Louis
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Institute of Clinical and Translational Sciences, National Institutes of Health, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNIT, WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNIT, Diabetes Research & Training Center, G2199452652, Washington University Institute of Clinical and Translational Sciences, Exercise & Pioglitazone for HIV-Metabolic Syndromes, G766674393, A Resource for Biomedical Mass Spectrometry, Washington University Institute of Clinical and Translational Sciences (UL1), G9000153645, G9000277914, Washington University Nutrition Obesity Research Center, Diabetes Research Center, Diabetes and Related Metabolic Diseases
OpenAlex ID: W2059154143
